C.M. Bidwell & Associates’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

C.M. Bidwell & Associates’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,240	Closed	-$164K	–	302
2015 Q3	$164K	Hold	8,240	–	–	0.04%	177
2015 Q2	$135K	Buy	8,240 +225	+3%	+$3.9K	0.03%	191
2015 Q1	$125K	Buy	+8,015	New	+$124K	0.03%	184
2014 Q2	–	Sell	-6,840	Closed	-$49K	–	314
2014 Q1	$49K	Buy	+6,840	New	+$58.5K	0.01%	203

Other funds holding SCMP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

C.M. Bidwell & Associates's SCMP Position: Q4 2015 in Review

C.M. Bidwell & Associates sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2015, closing a stake of 8,240 shares — an estimated $164K sold.

C.M. Bidwell & Associates first reported a position in SCMP in Q1 2014 and held it in 4 quarters. The position peaked at $164K in Q3 2015. 149 funds tracked by Wall St. Rank hold SCMP as of Q4 2015.

C.M. Bidwell & Associates reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
C.M. Bidwell & Associates sold 8,240 Sucampo Pharmaceuticals, Inc. shares in Q4 2015, an estimated $164K.
C.M. Bidwell & Associates first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
C.M. Bidwell & Associates's Sucampo Pharmaceuticals, Inc. position peaked at $164K in Q3 2015.
149 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2015.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2015, filed 12 Feb 2016.